Antibacterial Agents TRIZ Cases

Engineered probiotic bacteria secrete enterocin peptides to target Clostridium perfringens in poultry gastrointestinal tracts.

Segmented antibiotic regimens using Formula compounds reduce treatment duration while maintaining effectiveness against resistant Mycobacterium species.

Vaccine vectors encode specific antigenic polypeptides to elicit protective IgA antibody responses against Campylobacter infection.

Mixing liquid plant extract with dry powdered plant material absorbs residual moisture, eliminating inert carriers that dilute potency and reduce purity.

Aerosolized levofloxacin complexes with divalent cations reduce pro-inflammatory cytokines while minimizing systemic exposure.

Membrane-active polyamines restore antibiotic efficacy against resistant Gram-negative bacteria by increasing outer membrane permeability.

Standardized synthetic saccharides replace heterogeneous capsular polysaccharides, resolving manufacturing inefficiencies while maintaining immunogenicity.

Alpha O-conotoxin peptide blocks alpha9alpha10 nAChRs and NMDA receptors, resolving side effects from non-selective treatments.

Administering specific Lactobacillus strain combinations reduces inflammation while avoiding gastrointestinal side effects of traditional medications.

Humanized antibodies bind pertussis toxin protein S1-S4 conjugates to neutralize catalytic function, addressing antigenic drift resistance.

A non-ceramic calcium phosphate cement embeds bone-repairing drugs to promote local tissue regeneration.

Optimized polymer coatings regulate rapamycin diffusion to prevent restenosis while reducing thrombosis risks associated with paclitaxel.

Mycobacterium w components act as poly-TLR antagonists to mitigate pathological inflammation in sepsis and multiple sclerosis.

IL-33 cytokine therapy modulates host immunity via regulatory T-cells, reducing mortality and recurrence while preserving endogenous flora.

A 2-carboxypenam derivative exhibits strong antibacterial activity against Gram-negative bacteria.

A foamable sanitizing composition uses derivatized dimethicone to generate stable foam from alcohol solutions.

Interleukin-10 receptor-2 peptide antibodies block cytokine signaling to clear pathogens without suppressing animal growth.

Respirable dry powders deliver therapeutic agents to the respiratory tract, eliminating inert carriers and improving dispersibility.

Electrolyzed ORP water inhibits mast cell degranulation, resolving systemic toxicity risks from conventional anti-inflammatory therapies.

Novel spirohydantoin compound overcomes long treatment duration and drug resistance risks in Mycobacterium avium complex infections.

A fluorescent liposome assay detects phospholipase A2 activity using labeled substrates.

A modified Brucella strain with an inactivated wzm gene alters lipopolysaccharide structure to reduce serological test interference.

A biodegradable polymer coating incorporates lysozyme to inhibit bacterial growth on food contact surfaces.

Bicyclic heteroaromatic enantiomers inhibit bacterial methionyl tRNA synthetase to block protein synthesis.

A composition containing beta-glucogallin and Bacillus coagulans MTCC 5856 inhibits Helicobacter pylori growth.

Topical acidic composition with lignocaine and cetrimide treats foot and mouth disease lesions.

Larazotide peptide repairs damaged intestinal epithelium to reduce leakiness, preventing pathogen entry in necrotizing enterocolitis.

Bacteria expressing 00502 or 00509 proteins decompose trypsin to treat inflammatory bowel disease.

Cationic beta-cyclodextrin reduces silver ions to nanoparticles, eliminating toxic chemical reagents and improving water solubility.

Fusing conformationally stable adhesin with bacterial toxin subunits creates a chimeric immunogenic composition.

Combining hydrophilic Tween 60 and hydrophobic Span 60 surfactants maintains pexiganan drug concentration above 90% after long-term storage.

Carbamate compounds bind VLA-4 to reduce leukocyte adhesion, minimizing tissue damage in inflammatory diseases.

A soluble solid dosage form uses polyvinylpyrrolidone to enhance florfenicol wettability and dissolution.

Alpha-keto alkylperacid solutions reduce microbial populations by up to 99.9% while avoiding skin irritation and environmental harm.

Cannabinoid compositions kill resistant pathogens like Clostridium difficile while sparing healthy microbiota to prevent antibiotic resistance.

N-phenylpyrrolamide compounds inhibit ATPase domains of DNA gyrase and topoisomerase IV, reducing cytotoxicity and reactive metabolite production.

Heteroaryl compounds inhibit Syk, FLT3, JAK1, and JAK2 kinases to resolve the trade-off between single-target reliability and broad disease coverage.

Inactivated bacterial cells boost immune function without permanent colonization, eliminating the need for regular ingestion required by live probiotics.

Adipose-derived stem cells act as biological mediators to modulate immune responses, reducing mortality rates associated with severe sepsis and endotoxemia.

A topical composition combining niacinamide and picolinamide induces antimicrobial peptide secretion from keratinocytes.

A cryoprotectant mixture protects encapsulated cells during freeze-drying.